Oncternal Therapeutics (ONCT) Scheduled to Post Quarterly Earnings on Thursday

Oncternal Therapeutics (NASDAQ:ONCT) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($2.88) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Oncternal Therapeutics (NASDAQ:ONCT) last released its earnings results on Thursday, March 7th. The company reported ($3.11) earnings per share for the quarter, missing the consensus estimate of ($3.09) by ($0.02). Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative return on equity of 95.87%. The firm had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.17 million. During the same period in the prior year, the business posted ($4.00) earnings per share. On average, analysts expect Oncternal Therapeutics to post $-11 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Oncternal Therapeutics Trading Down 5.3 %

NASDAQ ONCT opened at $8.52 on Wednesday. The firm has a market capitalization of $25.22 million, a P/E ratio of -0.63 and a beta of 1.28. The firm’s fifty day moving average price is $8.78 and its two-hundred day moving average price is $8.36. Oncternal Therapeutics has a 1 year low of $5.57 and a 1 year high of $13.14.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Oncternal Therapeutics in a report on Friday, May 3rd. They issued a “hold” rating on the stock. HC Wainwright dropped their price objective on Oncternal Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, April 15th.

Insider Transactions at Oncternal Therapeutics

In related news, Director Robert James Wills purchased 3,086 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were acquired at an average price of $8.96 per share, for a total transaction of $27,650.56. Following the purchase, the director now owns 10,000 shares in the company, valued at $89,600. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders purchased 10,714 shares of company stock worth $92,736. 8.00% of the stock is owned by insiders.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.